治疗2型糖尿病新药那格列奈

被引:13
作者
蒋彦章
机构
[1] 中国药师编辑部武汉
关键词
那格列奈; 糖尿病; 2型;
D O I
暂无
中图分类号
R977.15 [];
学科分类号
1007 ;
摘要
<正> 2型糖尿病发病机制的特征为胰岛素分泌减少,胰岛素抵抗及肝脏葡萄糖生成增多,使体内糖代谢出现紊乱。欧美的糖尿病发病率约为2%~3%,美国有1030万糖尿病患者,其中90%以上为2型糖尿病。我国是世界上糖尿病高发的3个国家之一,其发病率约为2%~4%,目前患病总人数不低于3千万,预测到2010年将增加到6300
引用
收藏
页码:147 / 149+175 +175
页数:4
相关论文
共 10 条
[1]  
Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Hirschberg Y,Karara AH,Pietri AO,et al. Diabetes Care . 2000
[2]  
Effects of the new hypoglycemic agent nateglinide on insulin secretion in type 2 diabetes millitus. Whitelaw DC,Clark PM,Smith JM,et al. Diabetic Medicine . 2000
[3]  
Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. Luzio SD,Anderson Dm,Owens DR. Journal of Clinical Endocrinology and Metabolism . 2001
[4]  
Effect of insulinotropic agents nateglinide on KV and Ca(2+) channels in pencreatic beta-cell. Hu S,Wang S. European Journal of Pharmacology . 2001
[5]  
Effect of a new hypoglycemic agent, A-4166[(-)-N-(trans-4-isopropyl-cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glbenclamide. Ikenoue T,Okazaki K,Fujitanis et al. Biological and Pharmaceutical Bulletin . 1997
[6]  
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. Keilson L,Mather S,Walter YH et al. The Journal of Clinical Endocrinology . 2000
[7]  
The effect of food on the oralbioavilability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. Karara AH,Dunning BE,Mcload JF. Journal of Clinical Pharmacology . 1999
[8]  
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoqlycaemic agents, NN623 and A4166. Kikuchi M. Diabetic Medicine . 1996
[9]  
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Hanefeld M,Bonter KP,Dikinson S,et al. Diabetes Care . 2000
[10]  
Nateqlinide: a new rapid-acting insulinotropic agent. Hanif W,Kumar S. Expert Opinion on Pharmacotherapy . 2001